Please wait a minute...
文章检索
预防医学  2026, Vol. 38 Issue (3): 267-273    DOI: 10.19485/j.cnki.issn2096-5087.2026.03.011
  论著 本期目录 | 过刊浏览 | 高级检索 |
2016—2021年郑州市肿瘤登记地区甲状腺癌发病和死亡趋势分析
闫瑞平, 李建彬, 安戈, 郭向娇, 黄婼璇, 宋彩娟
郑州市疾病预防控制中心(郑州市卫生监督所),河南 郑州 450007
Trends in incidence and mortality of thyroid cancer in cancer registration areas of Zhengzhou City from 2016 to 2021
YAN Ruiping, LI Jianbin, AN Ge, GUO Xiangjiao, HUANG Ruoxuan, SONG Caijuan
Zhengzhou Center for Disease Control and Prevention (Zhengzhou Institute of Public Health Supervision), Zhengzhou, Henan 450007, China
全文: PDF(1087 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 分析2016—2021年郑州市肿瘤登记地区甲状腺癌发病和死亡趋势,为制定针对性的甲状腺癌防治策略提供依据。方法 通过郑州市各肿瘤登记处收集质量合格的甲状腺癌发病和死亡病例登记资料,计算粗发病率、粗死亡率;采用2000年第五次全国人口普查标准人口结构和Segi's世界标准人口结构分别计算中国人口标化率(中标率)和世界人口标化率(世标率)。采用平均年度变化百分比(AAPC)分析2016—2021年郑州市不同性别、年龄和城乡甲状腺癌发病率和死亡率的变化趋势。结果 2021年郑州市甲状腺癌粗发病率、中标发病率和世标发病率分别为42.55/10万、37.43/10万和32.56/10万,粗死亡率、中标死亡率和世标死亡率分别为1.07/10万、0.77/10万和0.71/10万。女性甲状腺癌中标发病率、中标死亡率分别是男性的2.64倍和2.83倍;城市分别是农村的2.25倍和1.51倍;55~<60岁组粗发病率达最高,为92.52/10万。2016—2021年甲状腺癌粗发病率和中标发病率呈上升趋势(AAPC=21.797%、22.725%,均P<0.05),不同性别、城乡趋势与全人群一致;20~<30岁、30~<40岁、40~<50岁、50~<60岁和60~<70岁组粗发病率呈上升趋势(AAPC=17.237%、31.026%、21.289%、23.010%和11.752%,均P<0.05)。2016—2021年甲状腺癌中标死亡率呈上升趋势(AAPC=15.196%,P<0.05),粗死亡率趋势无统计学意义(P>0.05);女性、农村粗死亡率(AAPC=21.078%、25.669%)和中标死亡率(AAPC=24.122%、28.865%)呈上升趋势(均P<0.05)。结论 2016—2021年郑州市肿瘤登记地区甲状腺癌中标发病率和中标死亡率均呈上升趋势,女性、城市居民和中青年人群是甲状腺癌防控的重点人群。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
闫瑞平
李建彬
安戈
郭向娇
黄婼璇
宋彩娟
关键词 甲状腺癌发病率死亡率平均年度变化百分比    
AbstractObjective To investigate the trends in incidence and mortality of thyroid cancer in cancer registration areas of Zhengzhou City, Henan Province from 2016 to 2021, so as to provide evidence for developing targeted thyroid cancer prevention and treatment strategies. Methods Data on incidence and mortality of thyroid cancer with qualified registration quality were collected from cancer registration offices in Zhengzhou City. Crude incidence and crude mortality were calculated. The Chinese population-standardized incidence and world population-standardized incidence were calculated using the standard age structure from the Fifth National Population Census in 2 000 and Segi's world standard population structure, respectively. The average annual percentage change (AAPC) was used to analyze the trends in the incidence and mortality of thyroid cancer in Zhengzhou City from 2016 to 2021 across different gender, age, and urban-rural area. Results In 2021, the crude incidence, Chinese population-standardized incidence and world population-standardized incidence of thyroid cancer in Zhengzhou City were 42.55/105, 37.43/105, and 32.56/105, respectively. The crude mortality, Chinese population-standardized mortality and world population-standardized mortality were 1.07/105, 0.77/105, and 0.71/105, respectively. The Chinese population-standardized incidence and mortality in females were 2.64 times and 2.83 times those in males, respectively; those in urban areas were 2.25 times and 1.51 times those in rural areas, respectively. The crude incidence peaked in the group aged 55-<60 years at 92.52/105. From 2016 to 2021, the crude incidence and Chinese population-standardized incidence of thyroid cancer showed an upward trend (AAPC=21.797%, 22.725%, both P<0.05), with trends consistent across different genders and urban-rural areas with the total population. The crude incidence showed upward trends in the groups aged 20-<30 years, 30-<40 years, 40-<50 years, 50-<60 years, and 60-<70 years (AAPC=17.237%, 31.026%, 21.289%, 23.010%, and 11.752%, all P<0.05). From 2016 to 2021, the Chinese population-standardized mortality of thyroid cancer showed an upward trend (AAPC=15.196%, P<0.05), while the trend in crude mortality was not statistically significant (P>0.05). The crude mortality (AAPC=21.078%, 25.669%) and Chinese population-standardized mortality (AAPC=24.122%, 28.865%) in females and rural areas showed upward trends (all P<0.05). Conclusions From 2016 to 2021, the Chinese population-standardized incidence and mortality of thyroid cancer in cancer registration areas of Zhengzhou City showed an upward trend. Females, urban residents, and middle-aged and young populations are key groups for thyroid cancer prevention and control.
Key wordsthyroid cancer    incidence    mortality    average annual percent change
收稿日期: 2026-01-08      修回日期: 2026-02-14      出版日期: 2026-03-10
中图分类号:  R736.1  
作者简介: 闫瑞平,硕士,主管医师,主要从事慢性病预防控制工作
通信作者: 宋彩娟,E-mail:huzhuang934@163.com   
引用本文:   
闫瑞平, 李建彬, 安戈, 郭向娇, 黄婼璇, 宋彩娟. 2016—2021年郑州市肿瘤登记地区甲状腺癌发病和死亡趋势分析[J]. 预防医学, 2026, 38(3): 267-273.
YAN Ruiping, LI Jianbin, AN Ge, GUO Xiangjiao, HUANG Ruoxuan, SONG Caijuan. Trends in incidence and mortality of thyroid cancer in cancer registration areas of Zhengzhou City from 2016 to 2021. Preventive Medicine, 2026, 38(3): 267-273.
链接本文:  
https://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2026.03.011      或      https://www.zjyfyxzz.com/CN/Y2026/V38/I3/267
[1] BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263.
[2] TANG S D,ZI H,TAO H,et al.Secular trends of morbidity and mortality of thyroid cancer in five Asian countries from 1990 to 2019 and their predictions to 2035[J].Thorac Cancer,2023,14(36):3540-3548.
[3] HAN B F,ZHENG R S,ZENG H M,et al.Cancer incidence and mortality in China,2022[J].J Natl Cancer Cent,2024,4(1):47-53.
[4] LI M M,DAL MASO L,PIZZATO M,et al.Thyroid cancer in adolescents and young adults:a population-based study in 185 countries worldwide[J].Lancet Diabetes Endocrinol,2026,14(2):112-122.
[5] 国家癌症中心.中国肿瘤登记工作指导手册(2016)[M].北京:人民卫生出版社,2016.
[6] 王少明,郑荣寿,韩冰峰,等.2022年中国人群恶性肿瘤发病与死亡年龄特征分析[J].中国肿瘤,2024,33(3):165-174.
[7] 伊可欣,郄然然,刘茵,等.2020年河南省恶性肿瘤发病与死亡特征及2010—2020年趋势分析[J].中国肿瘤,2025,34(11):829-837.
[8] 李佳佳,张小鹏,张俊青,等.2021年安徽省合肥市甲状腺癌流行特征及2013—2021年变化趋势分析[J].中国肿瘤,2025,34(3):188-194.
[9] 陈德芳,亓爱玲,王莹,等.2014—2023年济南市甲状腺癌流行特征及减寿分析[J].中国地方病防治,2025,40(2):104-108.
[10] DENARO N,ROMANÒ R,ALFIERI S,et al.The tumor microenvironment and the estrogen loop in thyroid cancer[J/OL].Cancers,2023,15(9)[2026-02-14].https://doi.org/10.3390/cancers15092458.
[11] LIU J,XU T M,MA L,et al.Signal pathway of estrogen and estrogen receptor in the development of thyroid cancer[J/OL].Front Oncol,2021,11[2026-02-14].https://doi.org/10.3389/fonc.2021.593479.
[12] LAM D,DAVIES L,SAWKA A M.Women and thyroid cancer incidence:overdiagnosis versus biological risk[J].Curr Opin Endocrinol Diabetes Obes,2022,29(5):492-496.
[13] 项彩英,陈颖,汪德兵,等.2021年浙江省肿瘤登记地区甲状腺癌发病与死亡特征及2000—2021年变化趋势分析[J].中国肿瘤,2025,34(10):756-763.
[14] LI M M,ZHENG R S,DAL MASO L,et al.Mapping overdiagnosis of thyroid cancer in China[J].Lancet Diabetes Endocrinol,2021,9(6):330-332.
[15] 马靖茹,王智奕,孙美晨,等.中国超重肥胖流行状况与防控工作进展[J].中国预防医学杂志,2024,25(4):406-412.
[16] FIORE M,CRISTALDI A,OKATYEVA V,et al.Dietary habits and thyroid cancer risk:a hospital-based case-control study in Sicily (South Italy)[J/OL].Food Chem Toxicol,2020,146[2026-02-14].https://doi.org/10.1016/j.fct.2020.111778.
[17] SAENKO V,MITSUTAKE N.Radiation-related thyroid cancer[J].Endocr Rev,2024,45(1):1-29.
[18] 胡君,周锋,姜涌斌,等.中青年甲状腺结节患者发生甲状腺癌的工作、生活行为方式影响因素[J].环境与职业医学,2024,41(2):200-206.
[19] 陈芳,吴凯,徐明星,等.基于病例对照研究的甲状腺癌危险因素的Meta分析[J].中华地方病学杂志,2017,36(4):250-256.
[20] 中华人民共和国国家卫生健康委员会医政医管局.甲状腺癌诊疗指南(2022年版)[J].中国实用外科杂志,2022,42(12):1343-1357,1363.
[21] 阿迪拉·苏力旦,夏依达·乌斯满江,沙吾拉西·热加甫,等.2020年新疆肿瘤登记地区甲状腺癌流行特征及2016—2020年变化趋势分析[J].预防医学,2025,37(10):1020-1023,1028.
[22] 韩亚蓉,韩颖颖,蔡波,等.2013—2022年南通市甲状腺癌发病和死亡趋势分析[J].预防医学,2026,38(1):20-25.
[1] 朱凯强, 唐慧玲, 陈依娜, 李卫丹, 张子根. 2015—2024年金华市肺结核流行特征分析[J]. 预防医学, 2026, 38(3): 237-241.
[2] 李海华, 叶勇, 袁瑞, 运靖宜, 王浩博, 傅雨欣. 2006—2025年湖州市儿童青少年糖尿病发病趋势及年龄-时期-队列分析[J]. 预防医学, 2026, 38(3): 257-262.
[3] 舒奇, 夏文霞, 李振娟, 朱晓云. 2003—2023年金山区居民伤害死亡与减寿趋势分析[J]. 预防医学, 2026, 38(2): 156-160,165.
[4] 仲玮, 李伟伟, 相璐, 柴莉莉, 董建梅, 马昭君, 秦绪成, 张伟伟. 2011—2029年连云港市慢性呼吸系统疾病死亡趋势及预测研究[J]. 预防医学, 2026, 38(2): 181-186.
[5] 韩亚蓉, 韩颖颖, 蔡波, 林玲. 2013—2022年南通市甲状腺癌发病和死亡趋势分析[J]. 预防医学, 2026, 38(1): 20-25.
[6] 周凡, 王小红, 陈梦倩, 张小兰, 徐则林. 2016—2027年金华市结直肠癌发病和死亡趋势分析及预测[J]. 预防医学, 2026, 38(1): 26-30.
[7] 卢文海, 孔校杰, 宋丽霞, 卢春如, 于碧鲲, 谢延. SARIMA、Prophet与BSTS模型预测手足口病发病率的效果比较[J]. 预防医学, 2026, 38(1): 79-84.
[8] 马荣娇, 黄涵焱, 朱镘羽, 刘瑞, 石芳. 1990—2021年中国归因于烟草的哮喘疾病负担趋势分析[J]. 预防医学, 2026, 38(1): 89-92.
[9] 李玉荣, 王冬飞, 高媛媛, 蒋园园, 林君英, 肖段段. 2010—2024年萧山区结直肠癌发病趋势分析[J]. 预防医学, 2025, 37(9): 927-931,936.
[10] 李君, 朱婷婷, 胡文雪. 2005—2023年温州市丙型病毒性肝炎流行特征分析[J]. 预防医学, 2025, 37(9): 932-936.
[11] 胡晓强, 刘艳, 周思凡, 张子喆, 王雨达, 沈建勇. 2014—2023年湖州市流行性感冒流行特征分析[J]. 预防医学, 2025, 37(9): 959-962.
[12] 李克, 庞志峰, 吴晓虹, 王诚, 何瑶, 唐慧玲. 2007—2024年金华市钩端螺旋体病流行特征分析[J]. 预防医学, 2025, 37(8): 818-821.
[13] 冷雪, 傅淑琴, 舒纪为, 谭启龙, 李科峰. 舟山市带状疱疹首诊病例特征分析[J]. 预防医学, 2025, 37(7): 701-704.
[14] 朱颖, 郑添. 2013—2023年嘉善县居民期望寿命变化[J]. 预防医学, 2025, 37(6): 598-602.
[15] 董沙沙, 项云飞. 2014—2023年余姚市原发性肝癌死亡与疾病负担分析[J]. 预防医学, 2025, 37(6): 603-607.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed